|
1
|
Li S, Mason CE and Melnick A: Genetic and
epigenetic heterogeneity in acute myeloid leukemia. Curr Opin Genet
Dev. 36:2810–106. 2016. View Article : Google Scholar
|
|
2
|
Juliusson G and Hough R: Leukemia. Prog
Tumor Res. 43:87–100. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
De Kouchkovsky I and Abdul-Hay M: Acute
myeloid leukemia: A comprehensive review and 2016 update. Blood
Cancer J. 6:e4412016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yamamoto JF and Goodman MT: Patterns of
leukemia incidence in the United States by subtype and demographic
characteristics, 1997–2002. Cancer Causes Control. 19:379–390.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pulte D, Gondos A and Brenner H: Expected
long-term survival of patients diagnosed with acute myeloblastic
leukemia during 2006–2010. Ann Oncol. 21:335–341. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Meyers J, Yu Y, Kaye JA and Davis KL:
Medicare fee-for-service enrollees with primary acute myeloid
leukemia: An analysis of treatment patterns, survival, and
healthcare resource utilization and costs. Appl Health Econ Health
Policy. 11:275–286. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bose P, Vachhani P and Cortes JE:
Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat
Options Oncol. 18:172017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McCall MN, Kim MS, Adil M, Patil AH, Lu Y,
Mitchell CJ, Leal-Rojas P, Xu J, Kumar M, Dawson VL, et al: Toward
the human cellular microRNAome. Genome Res. 27:1769–1781. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Acunzo M, Romano G, Wernicke D and Croce
CM: MicroRNA and cancer-a brief overview. Adv Biol Regul. 57:1–9.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang X, Chen H, Bai J and He A: MicroRNA:
An important regulator in acute myeloid leukemia. Cell Biol Int.
41:936–945. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li Q, Song W and Wang J: TUG1 confers
Adriamycin resistance in acute myeloid leukemia by epigenetically
suppressing miR-34a expression via EZH2. Biomed Pharmacother.
109:1793–1801. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Szymczyk A, Chocholska S, Macheta A,
Szczepanek D, Hus M and Podhorecka M: Assessment of microRNA
expression in leukemic cells as predictors of sensitivity to purine
nucleoside analogs, fludarabine and cladribine, in chronic
lymphocytic leukemia patients. Cancer Manag Res. 11:5021–5031.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ding C, Chen SN, Macleod RAF, Drexler HG,
Nagel S, Wu DP, Sun AN and Dai HP: miR-130a is aberrantly
overexpressed in adult acute myeloid leukemia with t(8;21) and its
suppression induces AML cell death. Ups J Med Sci. 123:19–27. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wei H, Cui R, Bahr J, Zanesi N, Luo Z,
Meng W, Liang G and Croce CM: miR-130a deregulates PTEN and
stimulates tumor growth. Cancer Res. 77:6168–6178. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yin S, Zhang Q, Wang Y, Li S and Hu R:
MicroRNA-130a regulated by HPV18 E6 promotes proliferation and
invasion of cervical cancer cells by targeting TIMP2. Exp Ther Med.
17:2837–2846. 2019.PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lagunas-Rangel FA, Chavez-Valencia V,
Gomez-Guijosa MA and Cortes-Penagos C: Acute myeloid
leukemia-genetic alterations and their clinical prognosis. Int J
Hematol Oncol Stem Cell Res. 11:328–339. 2017.PubMed/NCBI
|
|
20
|
Paschka P, Schlenk RF, Gaidzik VI, Habdank
M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K,
et al: IDH1 and IDH2 mutations are frequent genetic alterations in
acute myeloid leukemia and confer adverse prognosis in
cytogenetically normal acute myeloid leukemia with NPM1 mutation
without FLT3 internal tandem duplication. J Clin Oncol.
28:3636–3643. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kater L, Claffey J, Hogan M, Jesse P,
Kater B, Strauss S, Tacke M and Prokop A: The role of the intrinsic
FAS pathway in Titanocene Y apoptosis: The mechanism of overcoming
multiple drug resistance in malignant leukemia cells. Toxicol In
Vitro. 26:119–124. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Madanat YF, Kalaycio ME and Nazha A:
Advances in acute myeloid leukemia genomics, where do we stand in
2018? Acta Med Acad. 48:35–44. 2019.PubMed/NCBI
|
|
23
|
Rivankar S: An overview of doxorubicin
formulations in cancer therapy. J Cancer Res Ther. 10:853–858.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han YQ, Hong Y, Su XL and Wang JR:
Quercetin enhances the anti-leukemic effect of adriamycin. Zhongguo
Shi Yan Xue Ye Xue Za Zhi. 22:1555–1560. 2014.(In Chinese).
PubMed/NCBI
|
|
25
|
Kong X, Zhang J, Li J, Shao J and Fang L:
miR-130a-3p inhibits migration and invasion by regulating RAB5B in
human breast cancer stem cell-like cells. Biochem Biophys Res
Commun. 501:486–493. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang HD, Jiang LH, Sun DW, Li J and Ji
ZL: The role of miR-130a in cancer. Breast cancer. 24:521–527.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu Y, Li Y, Wang R, Qin S, Liu J, Su F,
Yang Y, Zhao F, Wang Z and Wu Q: miR-130a-3p regulates cell
migration and invasion via inhibition of Smad4 in gemcitabine
resistant hepatoma cells. J Exp Clin Cancer Res. 35:192016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu X, Zhao H, Lin Z and Zhang G:
Functional studies of miR-130a on the inhibitory pathways of
apoptosis in patients with chronic myeloid leukemia. Cancer Gene
Ther. 22:573–580. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Feng C, Ma F, Hu C, Ma JA, Wang J, Zhang
Y, Wu F, Hou T, Jiang S, Wang Y and Feng Y: SOX9/miR-130a/CTR1 axis
modulates DDP-resistance of cervical cancer cell. Cell Cycle.
17:448–458. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen T, You Y, Jiang H and Wang ZZ:
Epithelial-mesenchymal transition (EMT): A biological process in
the development, stem cell differentiation, and tumorigenesis. J
Cell Physiol. 232:3261–3272. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dominguez C, David JM and Palena C:
Epithelial-mesenchymal transition and inflammation at the site of
the primary tumor. Semin Cancer Biol. 47:177–184. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liao TT and Yang MH: Revisiting
epithelial-mesenchymal transition in cancer metastasis: The
connection between epithelial plasticity and stemness. Mol Oncol.
11:792–804. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee HH, Jung J, Moon A, Kang H and Cho H:
Antitumor and anti-invasive effect of apigenin on human breast
carcinoma through suppression of IL-6 expression. Int J Mol Sci.
20:31432019. View Article : Google Scholar
|
|
35
|
Serrano-Gomez SJ, Maziveyi M and Alahari
SK: Regulation of epithelial-mesenchymal transition through
epigenetic and post-translational modifications. Mol Cancer.
15:182016. View Article : Google Scholar : PubMed/NCBI
|
